%0 Journal Article
%T Nonhomologous end joining key factor XLF enhances both 5-florouracil and oxaliplatin resistance in colorectal cancer
%A Bingyuan Fei
%A Dongxin Wang
%A Jing Sun
%A Miao Yu
%A Zhuo Liu
%J Archive of "OncoTargets and therapy".
%D 2019
%R 10.2147/OTT.S192923
%X Colorectal cancer (CRC) is the third commonly diagnosed cancer with a high risk of death. After curative surgery, 40% of patients will have metastases or develop recurrence. Therefore, chemotherapy is significantly responsible as the major therapy method. However, chemoresistance is found in almost all metastatic patients and remains a critical obstacle to curing CRC
%K XLF
%K nonhomologous end joining
%K 5-florouracil
%K oxaliplatin
%K chemoresistance
%K colorectal cancer
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430989/